Q2 2020 Lumos Pharma Inc Earnings Call

13/8/2020 16:30

Llamada en conferencia Lumos Pharma Inc

Lumos Pharma Inc Conference call will be held on 13-ago-2020. During the earnings conference call's session Lumos Pharma Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Lumos Pharma Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. Our portfolio includes biologic and small-molecule immuno-oncology product candidates intended to treat a wide range of oncology indications. Our biologic product candidates are based on our proprietary HyperAcute® Cellular Immunotherapy technology, which is designed to stimulate the human immune system. Algenpantucel-L is our most clinically advanced product candidate from this platform with two Phase 3 clinical trials ongoing for patients with pancreatic cancer, one of which is expected to read out data during 2016. Our additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively.    
Leer más Llamada en conferencia

Lumos Pharma Inc (NLNK)

2503 South Loop Drive, Ames Iowa 50010, United States